KRAS and lung carcinoma: These functional mouse studies interpret the mutation profile from the Pan-Lung Cancer cohort, where loss to STK11 is predominantly occurs in adenocarcinoma, whereas loss of Pten is a rare event in the combination of activated Kras mutation.